On Friday, Tango Therapeutics Inc (NASDAQ: TNGX) opened lower -1.31% from the last session, before settling in for the closing price of $6.86. Price fluctuations for TNGX have ranged from $1.03 to $12.02 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 7.47% over the past five years. Company’s average yearly earnings per share was noted -12.29% at the time writing. With a float of $58.92 million, this company’s outstanding shares have now reached $108.11 million.
Let’s look at the performance matrix of the company that is accounted for 155 employees. In terms of profitability, gross margin is 83.79%, operating margin of -355.86%, and the pretax margin is -322.17%.
Tango Therapeutics Inc (TNGX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Tango Therapeutics Inc is 45.64%, while institutional ownership is 58.28%. The most recent insider transaction that took place on Feb 04 ’25, was worth 8,289. In this transaction General Counsel of this company sold 2,774 shares at a rate of $2.99, taking the stock ownership to the 68,570 shares. Before that another transaction happened on Feb 05 ’25, when Company’s General Counsel sold 2,556 for $3.16, making the entire transaction worth $8,081. This insider now owns 66,014 shares in total.
Tango Therapeutics Inc (TNGX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -12.29% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.61% during the next five years compared to 7.47% growth over the previous five years of trading.
Tango Therapeutics Inc (NASDAQ: TNGX) Trading Performance Indicators
Check out the current performance indicators for Tango Therapeutics Inc (TNGX). In the past quarter, the stock posted a quick ratio of 6.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.21, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach -1.29 in one year’s time.
Technical Analysis of Tango Therapeutics Inc (TNGX)
Tango Therapeutics Inc (NASDAQ: TNGX) saw its 5-day average volume 1.65 million, a negative change from its year-to-date volume of 1.75 million. As of the previous 9 days, the stock’s Stochastic %D was 88.78%.
During the past 100 days, Tango Therapeutics Inc’s (TNGX) raw stochastic average was set at 93.94%, which indicates a significant increase from 84.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.49 in the past 14 days, which was higher than the 0.33 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.94, while its 200-day Moving Average is $3.42. Nevertheless, the first resistance level for the watch stands at $7.07 in the near term. At $7.36, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.59. If the price goes on to break the first support level at $6.55, it is likely to go to the next support level at $6.32. The third support level lies at $6.03 if the price breaches the second support level.
Tango Therapeutics Inc (NASDAQ: TNGX) Key Stats
There are currently 108,394K shares outstanding in the company with a market cap of 733.83 million. Presently, the company’s annual sales total 42,070 K according to its annual income of -130,300 K. Last quarter, the company’s sales amounted to 5,390 K and its income totaled -39,880 K.
